Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders
(2013) In Dementia and Geriatric Cognitive Disorders 36(1-2). p.99-110- Abstract
- Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB... (More)
- Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB compared with either of the two A beta biomarkers individually. Conclusion: The use of the A beta(1-42)/A beta(1-40) ratio could improve the differentiation of AD from PDD and DLB. (C) 2013 S. Karger AG, Basel (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4272598
- author
- Nutu, Magdalena ; Zetterberg, Henrik ; Londos, Elisabet LU ; Minthon, Lennart LU ; Nägga, Katarina LU ; Blennow, Kaj ; Hansson, Oskar LU and Ohrfelt, Annika
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Amyloid-beta, Alzheimer's disease, Parkinson's disease, Immunoassays, Amplified luminescent proximity homogenous immunoassay
- in
- Dementia and Geriatric Cognitive Disorders
- volume
- 36
- issue
- 1-2
- pages
- 99 - 110
- publisher
- Karger
- external identifiers
-
- wos:000328327900009
- scopus:84880184530
- pmid:23860354
- ISSN
- 1420-8008
- DOI
- 10.1159/000353442
- language
- English
- LU publication?
- yes
- id
- c496ca1d-0235-41c2-a64c-f9cafb310b55 (old id 4272598)
- date added to LUP
- 2016-04-01 10:51:51
- date last changed
- 2022-04-12 18:24:07
@article{c496ca1d-0235-41c2-a64c-f9cafb310b55, abstract = {{Background: The well-established core biomarkers used to identify Alzheimer's disease (AD) overlap with other dementia disorders such as dementia with Lewy bodies (DLB) and Parkinson's disease with dementia (PDD). This study aimed to evaluate whether the cerebrospinal fluid (CSF) amyloid-beta (A beta)(1-42)/A beta(1-40) ratio, measured by a novel method, could improve the differential diagnosis of AD, DLB and PDD. Method: CSF levels of A beta(1-40) and A beta(1-42) in patients with PDD, DLB, AD, Parkinson's disease and controls were analyzed using an amplified luminescent proximity homogenous immunoassay along with conventional immunoassays. Results: The CSF A beta(1-42)/A beta(1-40) ratio increased discrimination of AD from PDD and DLB compared with either of the two A beta biomarkers individually. Conclusion: The use of the A beta(1-42)/A beta(1-40) ratio could improve the differentiation of AD from PDD and DLB. (C) 2013 S. Karger AG, Basel}}, author = {{Nutu, Magdalena and Zetterberg, Henrik and Londos, Elisabet and Minthon, Lennart and Nägga, Katarina and Blennow, Kaj and Hansson, Oskar and Ohrfelt, Annika}}, issn = {{1420-8008}}, keywords = {{Amyloid-beta; Alzheimer's disease; Parkinson's disease; Immunoassays; Amplified luminescent proximity homogenous immunoassay}}, language = {{eng}}, number = {{1-2}}, pages = {{99--110}}, publisher = {{Karger}}, series = {{Dementia and Geriatric Cognitive Disorders}}, title = {{Evaluation of the Cerebrospinal Fluid Amyloid-beta(1-42)/Amyloid-beta(1-40) Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders}}, url = {{http://dx.doi.org/10.1159/000353442}}, doi = {{10.1159/000353442}}, volume = {{36}}, year = {{2013}}, }